Zydus Cadila Gets Final Approval From USFDA To Market Diflunisal Tablets

Zydus Cadila has received the final approval from the USFDA to market Diflunisal Tablets in the strength of 500 mg, informed Cadila Healthcare on Tuesday.

It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi.

Meanwhile, Cadila Healthcare was trading lower by 0.3% at Rs 529.10 per share at 1140 hours IST on BSE. It hit a high of Rs 536.95 and a low of Rs 527.40 so far in the morning session.

The stock has delivered around 70% returns in a period of one year. It has outperformed both BSE Sensex and BSE Healthcare over a period of one year. Its closest peers are Lupin and Sun Pharmaceutical Industries.

Cadila Healthcare Limited, an integrated healthcare company, discovers, develops, manufactures, and markets a range of healthcare and pharmaceutical products worldwide.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.